Efficient estimation of the equity cost of public corporations is an essential component of calculating the required rate of return of real investment projects, and therefore the basis for a rational investment policy. The accepted methodology relies on the CAPM model to define the return risk premium, and the OLS method to estimate the beta risk coefficient required for calculating the premium. This study challenges the use of the OLS method for this task by demonstrating its vulnerability to the impact of stock return outliers caused by large, unpredictable, company-specific events. That impact is verified on a sample of U.S. pharmaceutical companies by comparing the OLS estimation performance with that of our proposed method based on Huber's Robust M (HRM) estimator, a related statistical method that follows a mixed return model identifying regular and outlier return components. Using the HRMestimated beta as a benchmark, we demonstrate that (1) outliers can substantially bias the OLS beta, (2) the bias is negatively correlated with company size, and (3) the size of the bias is often moderated but not eliminated by extending the estimation period. The latter finding suggests that a robust method like HRM is preferable where estimators ought to represent the behavior of the majority of historical data despite the presence of outliers. The risk of trusting the OLS beta is especially high when estimation must rely on a small sample.
I. Introduction
The U.S. pharmaceutical industry is characterized by a symbiotic relationship between a few old giants and numerous newer and smaller companies. The former specialize in manufacturing and marketing of established products and occasional acquisition of rights over promising new products. New products are researched and developed by risk-taking small companies in the expectation of an eventual acquisition by one of the giants. News announcements concerning pharmaceutical products, such as the outcome of a clinical trial, a regulatory decision, or a class action lawsuit, can have a dramatic impact on the stock price of a company with consequent return outliers. Although few and far between, outliers have the power to significantly alter a company's estimated beta.
A documented drawback of the OLS method in estimating the CAPM parameters of a single company lies in the sensitivity of this method to deviations from normal distribution, in this case due to outlier returns. The impact of outlier returns in this context is investigated by Martin and Simin (2003) , Gray et al. (2005) , and Genton and Ronchetti (2008) . 1 Evidence shows that in an extreme case, even a single outlier may significantly affect the CAPM regression estimates of a stock's alpha, beta, and variance. A misstated beta would lead to a misstated cost of capital, risking erroneous capital budgeting decisions. In view of evidence by Brunner et al. (1998) and Graham and Harvey (2001) that over threequarters of the U.S. companies rely on the CAPM to estimate their cost of capital, a disregard of this risk may entail a large-scale misallocation of resources and attached social cost. Across industries, the extent of the damage is likely to rise with the severity of return outliers.
One approach of mitigating the impact of outliers on estimated OLS parameters calls for the removal of those observations from the sample. Applying this procedure to a sample of Australian firms, Gray et al. (2005) obtain stock return models that outperform the unadjusted OLS beta, the unity beta 1 Martin and Simin (2003) and Genton and Ronchetti (2008) demonstrate the impact of outliers on the estimated parameters of the single-factor model. Gray et al. (2005) provide examples of such an impact on stock return models using Australian utility companies.
model, and Blume's (1975) methodology, Knez and Ready (1997) find that the Fama and French (1992) This paper proposes a flexible theoretical model of stock return with an outlier component, which follows Huber's (1964 Huber's ( , 1981 Robust M (HRM) estimator. The mathematical relationship of our model to the OLS provides a framework for measuring and testing the impact of return outliers on beta. 2 Examined are also the related questions of whether this impact is related to company size, and to what extent this impact can be mitigated or even eliminated by extending the estimation period.
The paper proceeds as follows. Section II describes the economic importance of the pharmaceutical industry in terms of its size, growth, and profitability. Section 3 details our sample and preliminary empirical results. Section 4 identifies outlier-provoking company-specific events of four companies and the magnitude of market reaction to those events. Section 5 examines the relationship between sample size and the OLS bias. Section 6 offers a summary and concluding remarks. 2 The mathematical relationship between the OLS and the HRM return-generating estimators are analyzed in P. Theodossiou and A. K. Theodossiou (2009) , Impact of Outliers on Stock Return Models: Implications for Event Studies and the Pricing of Risk, Working Paper. Those relations allow the use of the HRM methodology even when outlier returns should be measured at full length. Under the current political climate, a new government policy under consideration would rely on enhanced regulation and competition to limit the secular rise in health-care profits and costs to the growth rate of GDP. 4 A key ingredient of such a regulation would be an objective estimate of companies' cost of capital similar to the treatment of public utilities.
II. The Pharmaceutical Industry

III. Sampling and Preliminary Results
Our sample consists of 76 pharmaceutical companies reported on the CRSP database for which complete data are available for ten consecutive years between January 1980 and August 2008. Those companies engage in research and production of medicinal chemicals and botanical products, pharmaceutical preparations, in-vitro and in-vivo diagnostic substances, and biological products (SIC codes ranging from 2830 to 2836 in both CRSP and COMPUSTAT). Thirty-eight companies are excluded from the sample for having less than ten years of continuous monthly data. The second and third columns in Table 1 report the effect of the individual company on the cumulative share of industry capitalization in the form of decrement (second column) and increment (third column). As indicated by the summary statistics at the bottom of the table, 50%, 75%, and 90% of the smallest companies have a combined market capitalization of 0.51% (3.6 BB$), 2.88% (20.3 BB$), and 16.4% (116 BB$), respectively, in reference to the industry total of 706 BB$.
The distribution of market capitalization is further analyzed using a Lorenz curve and its Gini coefficient. Displays in Figure 1 , the Lorenz curve shows the cumulative percentage of capitalization contributed by any cumulative share of the smaller companies. It measures company size inequality in reference to the special case of a uniform distribution represented by a 45-degree diagonal line. The Gini coefficient reduces to a single ratio the information provided by the Lorenz curve. The area bounded between the Lorenz curve and the diagonal line of perfect equality is divided by the entire triangular area under the diagonal line. Perfect equality would be indicated by a ratio of zero, and perfect inequality by a ratio of one. Our Gini coefficient of 0.891 is consistent with the reality of an industry dominated by the performance of a small number of relatively large companies.
The fourth and fifth columns in Table 1 report the individual company average and standard deviation of monthly returns over the five-year sample period. The minimum, median, and maximum of the average monthly returns are -2.7% (Genta), 1.9%, and 7.2% (Advanced Magnetic), respectively. The average monthly return ranges between −1% and 5.5% for eighty percent of the companies, and between 0.5% and 2.8% for fifty percent of the companies. Sixty seven companies exhibit a positive average return, and nine companies a negative average return. When compounded, a monthly return of 1.94% is equivalent to an annual return of 25.97%, figures far higher than the average monthly return for the market as a whole, 0.97%, or it annual equivalent, 12.26%.
The minimum, median, and maximum standard deviation of monthly returns are, respectively, 5.1% (Abbot), 17.3% (Isis), and 51.3% (Genaera). The contemporaneous figure for the stock market at large is 4.02% while for eighty percent of the companies the standard deviation is between 6.8% and 26.4%, and for fifty percent of the companies it is between 10.3% and 21.7%. 
IV. OLS vs. HRM: Four Company Case Studies
The following examples provide preliminary evidence of the potential benefit from using the HRM estimator for calculating stock betas, especially in the case of growth stocks where company- 
Genaera
Founded in 1987 and headquartered in Plymouth Meeting, Pennsylvania, Genaera Corporation is a biopharmaceutical company that engages in the research and development of pharmaceuticals with a focus on obesity, anti-angiogenesis, and respiratory diseases. During the sampling period, the company's market capitalization ranges from $11 to $233 million with a monthly median value of $97 million. Table 2 reveals that the company's monthly return volatility (column 5) is considerably higher than that of the overall market (column 6) with the former sinking as deep as −45% and soaring as high as +339%. We note that these figures pertain to the company's total price volatility combining systematic and unsystematic risk. • March 2003: Nasdaq extends by 180 days the grace period for compliance with the minimum requirement of a $1 bid price, a condition for the company's continued listing on the Exchange. A price increase of 90.6 percent.
• April 2003: Correction of the previous decision. A price decrease of 32 percent.
• A price increase of 33.9 percent. This event is largely responsible for an upward shift in the OLS regression line and an increase in the line's slope (beta) to 3.123.
• • August 2003: Evidence that Squalamine improves vision in age-related macular degeneration.
Later that month, two related US patents are issued. A price increase of 63.6 percent.
• January 2004: A successful private placement of 4,950,500 common shares at $4.04 per share. The deal includes 990,100 warrants to purchase 990,100 additional shares. A price increase of 43.7 percent.
• August 2005: Executive VP John L. Armstrong is promoted to President and Chief Operating
Officer. A price increase of 52.1 percent.
• June 2006: Patent received on gene variants of the Interleukin-9 receptor. The company is given 180 days to regain compliance with Nasdaq's minimum bid requirements. A price decrease of 44.7 percent.
• (Table 2 , columns 5-6).
• September 2002: The company stock price temporarily increases by 37.8% on news of its collaboration with Eli Lily to produce and market a new generation therapy for type-2 diabetes. A price decrease of 10 percent.
• June 2005: Amylin and Eli Lily announce the launch of Byetta, an injection drug treatment for type-2 diabetes. A price increase of 31 percent.
• August 2005: the company announces promising results from an ongoing Phase-II study of Byetta.
A price increase of 75.5 percent. Monthly returns vary dramatically between −44% and 204%. Consistently, the OLS beta estimator is high at 5.2208, and so is the lower HRM beta at 3.5960. The steeper OLS regression slope is driven by two large positive returns in May and September 2003.
• October 2002: Spreading news that Nasdaq is looking to help companies like NeoRx that are in danger of delisting. A price increase of 66.9 percent.
• March 2003: Appointment of Jack Bowman as Executive Chairman and transfer of the company's listing from Nasdaq's national market to its small-cap market. A price increase of 55.1 percent.
• April 2003: The FDA lifts its hold on the clinical use of its Skeletal Targeted Radiotherapy for the treatment of multiple myeloma, a cancer of the bone marrow. A price increase of 204 percent.
• September 2003: Spreading analysts' news that the Black Box 5 generated a "buy" signal for the company's stock. The company undertakes conference calls to promote its Skeletal Targeted Radiotherapy product. A price increase of 120.3 percent.
• February 2006: An infusion of $65 million of private capital, a move which is expected to prevent insolvency and prolong the company's life for five years at its present spending rate. A price increase of 67.8 percent.
• Figure 2D ).
• October 2003: Reported earnings per share for the third quarter are $0.83 compared with $0.85 forecasted by Wall Street. In the same month the company announced the elimination of 4,400 jobs from its workforce. A price decrease of 12.6 percent. 5 The Black Box is a computer investing program consisting of a series of formulas that process data entered by investors to formulate optimal trading strategies. As suggested by its name, users need not understand the algorithm generating the results.
• September 2004: A worldwide voluntary withdrawal of the company's best-selling drug, Vioxx, following a study linking its use with a higher risk of heart failure and stroke. A price decrease of 25.8 percent.
• 
V. OLS and HRM vis. Sample Size
Real-life constraints often limit the period of measurement and related sample size. The samples we used so far to estimate individual stock betas consist of sixty consecutive monthly observations of a stock returns paired with those of the underlying market. In a modest sample, the presence of a few outlying observations may have a significant impact on the OLS-estimated CAPM parameters. The impact on beta would be mitigated in a larger sample provided outliers are randomly distributed in both tails of the return distribution.
To compare the power of the OLS and HRM methods to cope with outliers, we use side-by-side samples of different sizes where results based on the larger sample offer a benchmark for both methods.
For each company under each sample size, we estimate beta using both methods and calculate the difference , OLS i k i , β β − , hereafter referred to as the OLS bias. Table 3 presents several statistics of the OLS bias distribution for the 76 pharmaceutical companies using sample sizes from 5 to 15 years of monthly data.
The mean OLS bias of the entire sample of companies ranges from 0.17 in fifteen years to 0.27 in eight years (Table 3, Moreover, the rule of limited liability limits the scope of bad news by constraining the minimum share price at zero. Table 4 ).
Our results offer strong evidence that the impact of outlying observations on OLS-estimated beta tends to subside in a large sample. In a large majority of the companies studied, the OLS beta estimator is biased upwards. A positive bias in the five-year sample is likely to decrease by increased sample size, but remain economically significant. In contrast, only a small minority of the companies studied exhibit a negative OLS beta bias, which is likely to vanish in a large sample.
To further examine the relationship between the OLS bias and sample size, we run a simple regression of the bias of firm i in sample size S (years) against (S−5), the sample size in excess of five years. The following estimation model uses an interaction dummy variable to test for a differential impact of sample size on a negative and positive OLS bias: 
VI. Summary and Conclusions
We proposes a substitute for the OLS method in estimating the beta parameter, a key component of the estimated risk premium and overall cost of capital of the single company or project. Our proposed estimation method follows Huber's Robust M (HRM) methodology of mixed return, which makes our method resistant to return outliers -a known vulnerability of the OLS method. We undertake a battery of empirical tests comparing beta estimates of the two methods. To assess the adverse impact of outliers on the OLS-estimated beta of the single company, we use a sample of 76 Pharmaceutical companies to compare the two methods. Treating the difference between estimated OLS and HRM betas as an OLS bias, we show that the bias is negatively correlated with company size. Important company-specific events tend to have a larger impact on small companies as measured by the effects on the stock price, the OLS-estimated beta, and the beta bias. Overall, the frequency of a positive OLS bias far exceeds that of a negative bias.
To determine whether the OLS bias negatively correlates with sample size and may be diminished by extending the sampling period beyond five years, we gradually increase that period to fifteen years. Overall, both negative and positive biases tend to diminish as the sample size increases.
Despite this tendency, only negative biases are eliminated; positive biases remain economically significant.
Since the frequency of a positive OLS bias far exceeds that of a negative bias and cannot be eliminated by increasing the sample size, we conclude that a robust estimation method like HRM is preferable to the OLS to the extent that estimated parameters are expected to represent the majority of historical data.
We opened this paper with the statement that efficient estimation of the equity cost of public corporations is an essential component of calculating the required rate of return of real investment projects, and therefore the basis for a rational investment policy. Our evidence and that of other authors suggest that the original choice of the OLS as an estimation method for beta was a legitimate extrapolation of the effective role played by this method in the multi-asset context of portfolio selection.
In that context, company-specific return volatility, including that of outliers, is largely diversified away even with limited diversification. Later contributions, like that of Blume (1975) , added a cachet to the OLS and extended its life by improving its efficiency in the context of capital budgeting. In a world of uncertainty, a damage caused by an unknown beta bias will rarely expose the source of the damage. The relative performance of our model strongly suggests that robust estimators offer a promising alternative to the OLS in cost of capital estimation of the single company or project. The confirmed vulnerability of OLS beta estimates to the impact of outliers is a warning to those who must rely on a small sample.
Appendix: Statistical Methodology
Following Roll (1988) , we model returns of individual stocks using a mixed return process with regular and outlier components. 6 This process allows for significant jumps (outliers) in the distribution of returns. The jump diffusion process, often used to price derivative assets, is the continuous analog of the mixed return process. Although the regular component distribution can be assumed normal, under the appropriate parameterization of the outlier component, the (overall) return can exhibit various levels of kurtosis and skewness. As such, the mixed return process is in line with empirical regularities in stock returns.
The general format of the mixed return process is:
where
t is the return of stock i during period t, K i,t and d i,t H i,t are the regular and outlier components of company i's stock return, d i,t is a dichotomous (Bernouli) random variable that takes the value of unity
with probability q when an outlier is present, and the value of zero with probability (1-q) otherwise, i = 1, 2,..., N, t =1, 2,..., T, N is the number of stocks, and T is the number of historical return observations.
In the context of the general stock return model, the above mixed return model is written as: Our estimation of the regular return regression is based on Huber's Robust M (HRM) estimator. Huber (1964 Huber ( , 1973 shows that when data follow a mixed probability distribution process, robust M 
7 A review of the estimation and statistical properties of Huber's method can be found in Judge et al. (1985) , Ch. 20. pp. 828-834; see also Huber (1981) . For a thorough analysis of robust estimation methods, see Hampel et al. (1986) . An extensive review on outliers in statistics can be found in Beckman and Cook (1983) .
where is as defined above. The HRM estimators for the regression intercept and slope satisfy the following normal equations (first order conditions for minimization),
These equations are solved iteratively using the algorithm 
σ is the HRM estimator for 
and m i is the proportion of untrimmed returns of company i. Standard errors for the estimator are 
Excess or abnormal returns of individual stocks are computed from the data using the equation
and outlier excess returns from , ,ˆî t i t i t , 
